FiercePharmaOriginal article
{"a":[{"_":"Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability","$":{"href":"/pharma/gilead-hiv-prep-franchise-hits-1b-quarterly-sales-analyst-questions-yeztugo-durability","hreflang":"en"}}]}
EarningsYeztugoPositive
AI Analysis
Summary
Gilead's HIV prevention franchise exceeded $1 billion in quarterly sales for the first time, driven by Yeztugo, though analysts question the drug's long-term durability and growth potential.
Financial Highlights
Revenue
$1 billion quarterly sales
Importance:5/10
Sentiment:
0.30
HIVPrEPcommercial_milestonelong-actinganalyst_concerns
Related Companies
Read the original article
Published by FiercePharma on August 5, 2026 10:50 AM